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Abstract

Cystinuria is an autosomal recessive disorder characterized by a defective renal transporter
involved in the reabsorption of cystine and other dibasic amino acids. This leads to an
accumulation of cystine in the urine, resulting in cystine stones. The SLC3A1/SLC7A9 cystine
transporter accounts for 90% of cystine reabsorption and mutations in this transporter result in
the formation of cystine stones. For this study, micro-computed tomography (µCT) scanning was
evaluated for its feasibility to track accurate volumetric measurements of in vivo cystine stone
growth in the Slc3a1-/- cystinuric mouse model. Six pharmacological interventions –
sulforaphane, methyl selenocysteine, homocysteine, tiopronin, TPEN and a zinc-supplemented
diet– were also examined for their efficacy in reducing the rate of cystine stone growth. µCT
analysis revealed stone growth proceeds linearly. Sulforaphane and TPEN supplementation
resulted in a reduced rate of stone growth when compared to the respective vehicle controls;
however, methyl selenocysteine and the zinc-supplemented diet displayed no effect on the rate or
nature of stone formation. Homocysteine and tiopronin were shown to worsen stone growth rate.
Sulforaphane and TPEN were effective interventions and our findings support both as a potential
therapy for a cystinuric mouse model. A combination of treatments targeting the rate of cystine
stone formation through similar agents appears to be a novel approach in further understanding
cystine stone growth. Therapies that can manage the balance between these agents and adverse
side effects provide an avenue to effectively treating cystinuria.
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Introduction
Cystinuria is an autosomal recessive disorder characterized by mutation(s) in the genes
that code for the cystine transporter. This disorder causes a defect in the proper reabsorption of
cystine (or cystine dimmers) in the proximal tubule of the nephron (Figure 1). Cystine is
produced endogenously from methionine or from a disulfide bond between two molecules of
cysteine. Due to the defect in cystine transport, cystine accumulates in the urine and eventually
forming small stones and larger stones. Without proper intervention, this leads to renal colic
(flank pain) while passing, urinary obstructions and lastly, renal failure if not treated (Evan,
2010).

1

.
Figure 1: Kidney Nephron Structure (Tikekar, 2014). The diagram depicts the parts of the
nephron. This study focuses mainly on the proximal convoluted tubule.
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I.

Epidemiology of Cystinuria
Cystinuria accounts for one to two percent of all kidney stone cases in adults and six to

eight percent in children (Botzenhart, 2002; Eggermann, 2012). It is one of the more common
inherited genetic disorders (Matoo, 2008) that eventually leads to renal failure due to a 60%
recurrence rate in at least 50% cystinuric patients (Claes, 2012). Five percent of women and
twelve percent of men develop a cystine-based stone at least once during their lifetime with 40%
of familial history matching in children cases (Eggermann, 2012; Pearle, 2005). These figures
may be an underestimation of the true prevalence since cystinurics may not actually develop a
stone in their lifetime and therefore, evade statistical prevalence.

II.

Pathophysiology
Stone formation is thought to arise from one of three pathways: overgrowth on interstitial

plaques, formation of crystal deposits in the renal tubules or crystallization in free solution
(Claes, 2012; Coe, 2010; Evan, 2006). Cystine stones mainly arise from the third pathway. The
defective transporter leads to accumulation of cystine in the urine. Due to its poor solubility in
urine, a supersaturated solution is created, where homogenous or heterogeneous nucleation can
occur. This eventually leads to the formation of crystals that plug the ducts of Bellini; however,
this mechanism of the anchorage is poorly understood. The crystals are thought to aggregate to
form free-floating cystine-based stones that eventually grow in size.
A. rBAT-b0,+ AT Transporter
The rBAT-b0,+ AT transporter, composed of the SLC3A1 and SLC7A9 protein subunits,
is characterized as a cystine and dibasic amino acid reabsorption transporter. The SLC3A1
subunit encodes for rBAT protein while the SLC7A9 subunit encodes for the bo,+, AT (Calonge,
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1994; Feliubadalo, 1999). This transporter accounts for an estimated 90% of cystine reabsorption
(Silbernaglet, 1988). In an unaffected individual, cystine and other dibasic amino acids are
filtered by the glomerulus and are reabsorbed across the apical membrane of the proximal tubule
through the rBAT-b0,+ AT transporter. Once cystine and the dibasic amino acids are transported
in the proximal tubule cell, intracellular cystine is readily reduced to two molecules of cysteine
(Figure 2). In a cystinuric patient, cystine is not reabsorbed through the rBAT-b0,+ AT transporter
and therefore, accumulates in the urine, leading to the formation of its stones.

4

Figure 2: Cystine Reabsorption in an Unaffected Individual and in a Cystinuric Patient. Adapted
from Mattoo, 2008. Cystine and the dibasic amino acids are transported across the apical
membrane through the rBAT- b0,+ AT transporter, the SLC3A1 and SLC7A9 heterodimer. Once
inside, cystine is reduced to two molecules of cysteine. Mutations in either the SLC3A1 or
SLC7A9 subunit cause a defective transporter. Due to the defective transporter, cystine is not
reabsorbed, leading to its accumulation in the urine and eventually, the formation of cystinebased stones.
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B. xc- Cystine-Glutamate Transporter
In addition to the rBAT- b0,+ AT transporter, an alternate transport system, known as the
xC- Cystine-Glutamate Transporter, is classified as a high affinity low capacity system (Palacin,
2001; Fernandez, 2002). It is composed of the SLC3A2 and SLC7A11 protein subunits and is
responsible for approximately 10% of cystine reabsorption in the apical membrane of the S3
segment of the proximal tubule (Mattoo, 2008). This transporter works by exchanging cystine
with glutamate. In addition, studies have shown that SLC7A11 is regulated by the transcription
factor, Nuclear Factor-like 2 - (Nrf2) (Ishii, 2000) (Figure 3). Nrf2 is commonly in the cytoplasm
bound to Keap1, its inhibitor. However, through the dissociation of the Nrf2-Keap1 complex,
Nrf2 is translocated into the nucleus, where its binding to the Antioxidant Response Element
(ARE) motif, leads to its activation (Sasaki, 2002). This activation then leads to increased
transcription of many genes and pathways including the xC- Cystine-Glutamate Transporter
(Johnson, 2008; Singh, 2006).

6

Figure 3: Cystine transport in the xC-Cystine-Glutamate System (Porcheray, 2006; Ishii, 2000;
Sasakim 2002). This process accounts for 10% of cystine reabsorption. Cystine is exchanged
with glutamate. Once in the tubular cell, cystine is reduced to two molecules of cysteine and
exits into the bloodstream.
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III.

Slc7a9-/-andSlc3a1-/- Mouse Models
To study the rBAT-b0,+ AT transporter in vivo, Slc7a9-/- mice were generated and have

become a model for cystinuria and cystine urolithiasis (Feliubadalo, 2003). In this study, the
expression of the rBAT protein and b0,+ AT protein was evaluated. The Slc7a9-/- mice were
shown to express large amounts of rBAT protein and decreased levels of b0,+ AT protein. In
addition, at least 42% of the Slc7a9-/- mice formed cystine stones that continued to grow
throughout the lifespan of the mouse.
Recently, the Slc3a1-/- mouse model was created and tested for its efficacy in studying
cystinuria as well (Ercolani, 2010). All the male Slc3a1-/- mice had shown the formation of
cystine stones that were visualized under a µCT scanner and upon dissection of the bladders, the
number of stones ranged from a few to over 15 in number. Bladder function was also evaluated
and partial outlet obstruction was found due to poor compliance and contractile responses. With
both models, cystinuria can be further studied and advances can be made to target either gene
deficiency.

IV.

Diagnosis
Diagnostic approaches are mainly focused on metabolic screens and imaging evaluations.

Metabolic screens include spot urine samples, fasting blood samples and 24-hour urine
collections to measure cystine excretion, volume, etc. 24-hour urine collections typically exhibit
high cystine concentrations during the night. Due to this, cystine analysis of separate day and
night samples may be needed to detect proper cystine excretion levels (Fjellstedt, 2001). Normal
cystine excretion is 30 mg/L per day. However, cystinuric patients excrete cystine anywhere
from 300-400 mg/L per day.
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Imaging screens include microscopic evaluation, ultrasound and computed tomography. Microscopic
evaluation reveals the characteristic hexagonal crystal formations of cystine stones (Knoll, 2005). The
ultrasound is one of the preferred routes and is used for newly developed stones, while computed
tomography is preferred for characterization of stone appearance as rough or smooth. This rough or
smooth distinction is then used to determine the efficacy of extracorporeal shock wave lithotripsy, a
process used for stone dissolution.

V.

Treatments
While the pathophysiology and genetics are well characterized, there’s been little

progress in finding an effective drug treatment. Medical management primarily consists of
reducing the free cystine concentration and/or increasing cystine solubility in the urine through
dietary modifications, urine alkalinization, sulfhydryl agents and surgical interventions. Current
medications rely heavily on sulfhydryl agents that have the ability to bind to cysteine and
increase the solubility of the asymmetric disulfides formed. Agents such as D-penacillamine
(DP), α-mercaptoproprionyl-glycine (MPG), captopril, and tiopronin are frequently used yet the
efficacy is limited. However, even with these techniques, poor compliance, adverse side effects
and the limitations with current medications still do not prevent cystine stone formation (Barbey,
2000).
A. Dietary Modification and Urine Alkalinization
Cystinuric patients are recommended a diet consisting of: hyperhydration (4-5 L per day),
a sodium-restricted diet (2g per day) and a protein-restricted diet (1g per day) (Knoll, 2005). The
goal of hyperhydration is to supersaturate urinary cystine at physiological pH. Previous studies
have correlated hyperhydration, before bed and upon awakening, with a reduction in cystine
saturation in the urine (Claes, 2012; Monnens, 2000; Fjellstedt, 2001). This ensures dilute urine
9

overnight. A low sodium intake has been previously shown to lower cystine excretion and is
recommended for cystinurics; the mechanistic action of this effect is unknown. However, the
known precursor to cysteine is methionine (Knoll, 2005) that is found low amounts in proteinrich foods (Fattah, 2014; Rodman 1984).
In addition, urine alkalinization has been shown to be a beneficial treatment for
cystinurics. Cystine solubility is known to increase by threefold with an increase in pH (Dent,
1955). High pH of 7.5 for cystinurics is recommended. However, a pH higher than 8 usually runs
the risk of forming calcium phosphate stones (Knoll, 2005). Potassium citrate and sodium
bicarbonate are compounds given to increase pH in urine (Fjellstedt, 2001). Sodium bicarbonate
is mainly administered to renal insufficient patients, while potassium citrate is recommended for
most other cases.
B. Pharmacological Intervention: Sulfhydryl Agents
Chelating and sulfhydryl agents have been used in the past when other treatment
measures failed. However, they now are becoming the primary choice. These agents are often
employed when cystine concentration reaches 2000 µmol/L or greater. Agents such as Dpenicillamine (DP), α-mercaptoproprionyl-glycine (tiopronin), captopril etc. are recommended
for their ability to bind to cysteine, forming asymmetric disulfides that are hypothesized to be
more soluble in urine (Harbar, 1986; Pak, 1986; Crawhall, 1963; Xu, 2013). This increased
solubility reduces the formation of cystine stones.
Tiopronin has been shown to present fewer side effects such as edema, hypouresis and
nephrotic syndrome than DP and is frequently recommended by physicians (Pak, 1986; Fattah,
2014). A study conducted by Chow et al. (1966) revealed that patients who did not experience
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the effects of hyperhydration and alkalinization treatments displayed a reduced rate of cystine
stone growth when treated with DP and tiopronin. Lastly, captopril is an angiotensin-converting
enzyme inhibitor that contains a thiol group. A study conducted by Asplin et al. (2013) revealed
that administration of captopril increases cystine solubility while increasing urinary pH in in
vitro studies; however its effectiveness is debated (Chow, 1996; Cohen, 1995; Goldfarb, 2006;
Asplin, 2013). Combinations of sulfhydryl agents have been suggested though haven’t been
researched yet (Tiselius, 2001).
C. Prospects for New Interventions
There are four steps in the formation of cystine stones – nucleation, crystallization,
aggregation and adhesion to nearby cells (Mandal, 2013). Current medications are known to
mediate the effects of nucleation by reducing the cystine accumulation in the urine or by
increasing cystine solubility. A study by Rimer et al (2010) revealed a new molecular approach
in preventing cystine stones by focusing on the crystallization and aggregation steps. The design
was based on an in vitro crystal growth inhibition model that was attained through the binding of
L-cystine dimethylester (L-CDME) and L-cystine methylester (L-CME) to cystine crystals.
Different binding modes were revealed in cystine crystals when treated with L-CDME and LCME, indicating that similar compounds can be administered to affect the binding and packing
modes of the cystine crystals. In a recent study conducted by Lee et al. (2015), administration of
CDME and CME to the Slc3a1-/- mice model displayed both candidates to be effective inhibitors
of the crystallization stage in cystine crystal growth. This novel approach to understanding
cystinuria through binding and packing modes of cystine crystals provides newer avenues to
targeting the steps of cystine stone formation.
D. Surgical Intervention
11

Surgical interventions, such extracorporeal shock wave lithotripsy (SWL), ureteroscopy
(URS) and percutaneous nephrolithotripsy (PNL), are commonly suggested due to their high
success rate and their safety. Computed tomography reveals the appearance of cystine stones as
either rough or smooth. From this, SWL, the most preferred route by physicians, is employed.
This non-invasive procedure is used for patients with a stone in the upper urinary tract (Kim,
2007; Kachel, 1991; Brinkmann, 2001; Muslumanoglu, 2003; Delakas, 2001). Previously,
cystine stones were thought to be resistant to shock wave lithotripsy (SWL) (Harada, 1992).
However, a study conducted by Bhatta et al. (1989) and later confirmed by Elkoushy et al.
(2011) reported that cystine stones with rough morphology were more susceptible to SWL than
those with smooth morphology. URS is also used for patients with stones in the upper urinary
tract. However, optimal results occur in patients with distal ureter stones (Schuster, 2002;
Choong, 2000). Lastly, PNL is used in cases where there are larger sized stones.

VI.

Proposed Pharmacological Interventions

A. Sulforaphane
Sulforaphane is an isothiocyanate molecule and is part of the organosulfur group. It is
known to exhibit anticancer, anti-diabetic and antioxidant properties due to its Nrf2 activator role
(Zheng, 2011; Hwang, 2015). Studies have shown that sulforaphane, when administered to wildtype and Nrf2-/-mice, can be detected in the small intestine, lungs, and kidney (Clarke, 2011;
Elbarbry, 2011; Cui, 2012). A recent study conducted by Zheng et al. (2011) has shown that
sulforaphane rescues diabetic nephropathy through an Nrf2-dependent pathway. This suggests
that sulforaphane is likely to be deliverable to the kidney and can activate Nrf2 in the renal
epithelial cells of the proximal tubule. By administering sulforaphane, Nrf2 activation is
hypothesized to promote the expression of Slc7a11 and thus, increase cystine reabsorption (Fig.
12

4). From this, we predict that the defective cystine reabsorption will be rescued by promoting the
use of the xc- system
B. Methyl Selenocysteine
Metallomics or kidney stone metal profiling has revealed amounts of selenium (Se) in
human and mouse cystine-based stones (Killilea, unpublished, Figure 4). Se is known to exist in
trace amounts in biological systems in organic (predominantly as selenocysteine and
selenomethionine) or inorganic (selenite, SeO32- and selenate, SeO42-) forms (Sunde, 2006;
Zhang 2008). However, its appearance in both human and mouse cystine stones provides an
avenue for testing a new in vivo approach to cystinuria.
An in vitro study by Rimer et al (2010) revealed a new molecular approach in preventing
cystine stones. The design was based on in vitro crystal growth inhibition attained through the
binding of L-cystine dimethylester (L-CDME) and L-cystine methylester (L-CME) to cystine
crystals (Rimer, 2010). Different binding modes were revealed in cystine crystals treated with
these interventions. For the purpose of our study, Se-methyl selenocysteine (methyl
selenocysteine) was similarly hypothesized to readily convert to selenocysteine and interact with
endogenous renal cysteine to generate asymmetric cysteine-selenocysteine disulfides. The
difference in atomic radii between selenium and sulfur is expected to impact the packing of these
heterogenous cystine stones, resulting in a reduced rate of cystine stone growth.
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Figure 4: Metallome Analysis of Human and Mouse Cystine Stones. (Killilea, unpublished data).
Kidney stone metal profiling revealed amounts of selenium in cystine-based stones when
compared to the calcium and uric acid stones. <DL : Below Detection Limit.
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Methods
I.

Overview

The Slc3a1-/- mouse, in a mixed genetic background of A129 and C57Bl/6J, develops cystine
stones in the bladder (Ercolani, 2010). These stones develop in the first 2-3 months of life and
grow throughout the lifespan of the mouse. All procedures and protocols were conducted
according to the Institutional Animal Care and Use Committee (IACUC), approved by the Buck
Institute for Research on Aging.

II.

Genotyping – DNA Extraction and Amplification
The Slc3a1-/- mice were genotyped using a modified version of the REDExtract-N-Amp

Tissue PCR protocol (Sigma-Aldrich, St. Louis, MO) (Amrik Sahota, Rutgers). 2mm tail clips
were obtained and added to 100μL extraction buffer solution and 25 μL tissue preparation
solution, following incubation at room temperature for 10 minutes and then inactivation at 95°C
for 3 minutes. Samples were then neutralized by adding 100μL neutralization buffer solution.
For each PCR reaction, 2μL DNA sample were mixed with 8μL of the PCR Master Mix
(Table 1) to a final volume of 10μL. All primers used in this study were synthesized by IDT
technologies, San Diego and are listed in Table 2. The PCR cycling parameters were set to 3
minutes at 94°C (94°C, 40 seconds, 58°C, 40 seconds, 72°C, 60 seconds X 35 cycles) and 7
minutes at 72°C. This standard PCR protocol was used to amplify the wild-type and Slc3a1-/alleles. 1.5% Agarose gel electrophoresis was conducted to identify the products.

15

Table 1: PCR Master Mix.

PCR Mix

Amount per Reaction

Water

2.7μL

REDExtract-N-Amp PCR Reaction Mix

5μL

10 uM Primer 1

0.1μL

10 uM Primer 2

0.1μL

10 uM Primer 3

0.1μL

DNA sample

2μL
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Table 2: PCR Primers.

Primer

Primer Sequence(5’-3’)

Molecular Weight
(Base Pairs

Primer 1

AGAATGTCTTCACTTCTGCCA

6356.2

Primer 2

CGAGACTAGTGAGACGTGCTA

7088.6

Primer 3

CTGCCTCCCGCATGCTGAGAT

6975.6

17

III.

Experimental Design

A. Drug Preparation
All drugs were freshly prepared daily prior to administering. Each cohort received the
respective dose administered daily or three times per week through intraperitoneal (IP) injections
for the duration of the study. R,S-sulforaphane (IDT Technologies, San Diego, CA) was kept in a
stock solution of 40mg/mL DMSO and was administered in 6.25% DMSO in PBS at 25mg/kg
body weight. Methyl selenocysteine hydrochloride (IDT Technologies, San Diego, CA) was
dissolved in 6.25% DMSO in PBS and administered at 100µg/kg body weight. Control mice
received vehicle only (DMSO+PBS). Mice were randomized to avoid bias before being placed in
the treatment groups. Preparation and dosage are summarized in Table 3.
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Table 3: Preparation and Doses for Sulforaphane and Methyl Selenocysteine Hydrochloride.
Treatment

Preparation

Dosage

R,S-Sulforaphane

Stock Solution in 40mg/mL

25mg/kg body weight

DMSO
Administered in 6.25%
DMSO in PBS
Methyl Selenocysteine

Dissolved in 6.25% DMSO in

Hydrochloride

PBS

19

100µg/kg body weight

B. Cystine Stone Growth Detection Using the Micro-Computed Tomography in
vivo(µCT)Scanner
A noninvasive method to detect stone growth was employed using the µCT scanner
(SkyScan 1176, Bruker, Belgium) for this study. All mice received general anesthesia through
inhalation of 1.5-4% isoflurane before and during the scanning period and were placed in a
supine position in the scanner. Low resolution (35 µm) scans were performed at the level of the
bladder using the following settings: X-ray voltage = 50 kV, anode current = 500 µA, exposure
time = 4 minutes, rotation step = 0.3°, averaging = 2, image pixel size = 35 mm, and filter = Al
0.5 mm. µCT scans were obtained weekly for the duration of the studies to track and measure the
rate of cystine stone growth.
C. Cystine Stone Growth Analysis
The stones are radiolucent and appear on the µCT scan (Figure 5a). Images were
reconstructed as cross-sectional three-dimensional (3D) image stacks using the software, Nrecon
(Nrecon v1.6.9.8, Bruker-MicroCT, Belgium). The dynamic range parameter (-0.002 to 0.08)
was set to minimize background noise and ensure the consistency between each individual
mouse scans. The 3D image stacks were exported to the image analysis software, CT Analysis
(CTAn v1.14, Bruker-MicroCT, Belgium). A threshold between 70 and 120 was chosen to
obtain better contrast between the bladder wall and stones. Following, circular regions of interest
(ROI) were drawn individually for each scan to enclose the bladder region. The rate of stone
growth was detected and quantified into 3D volumetric measurements, provided by the CTAn
package. 3D models of the stones were visualized using CT Volume (CTvol v2.0, BrukerMicroCT, Belgium) (Figure 5b).
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Figure 5: A) Representative μCT scan of a bladder from a control male cystinuric with stones. B)
3D model of a control male mouse tracked over a month.
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IV.

Statistical Analysis

Linear mixed model with random intercept was used for analyzing and modeling
longitudinal data to track the rate of stone growth by accounting for each individual mouse and
the different baselines the stone events occurred at. The Kaplan Meier estimate was employed to
track the rate of stone occurrence after a given time point and to determine whether interventions
had preventative properties. The statistical package, R, was used to analyze the collected data.
p<0.05 was considered statistically significant.
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Results
I.

Confirmation of Cystine-Based Stone Formation
A total of 17 male cystinuric mice were observed under the µCT scanner to ensure the

formation of cystine stones prior to the study initiation. Stone formation in the bladder was
detected in all the Slc3a1-/- mice prior to treatment. The number of stones and sizes varied among
the mutant mice. At the age of three months, the Slc3a1-/- mice were placed in three cohorts –
vehicle control (n=6), sulforaphane (n=5) and methyl selenocysteine (n=6). The interventions
were administered daily with IP injections and observed weekly for one month using the µCT
scanner.
Linear mixed model with random intercept was used to compare the rates of stone growth
between the treatment groups. Stone growth for the treatment groups proceeded at a linear rate
(Figure 6). Sulforaphane was significantly different from methyl selenocysteine (p=0.02).
However, neither sulforaphane nor methyl selenocysteine were statistically different from the
vehicle control group (Table 4). However, an interesting finding revealed that single stones may
increase in size as the total stone volume increases, contributing to large stone accumulation. By
tracking a single stone in a control mouse for one month, the rate of a single stone was shown to
increase linearly (Figure 7) with a correlation coefficient (R2) of 0.96.

23

Figure 6: Volumetric Analysis of Cystine Stones in the Bladder of Slc3a1-/- Mice. Regions of
Interest (ROIs) were drawn encompassing the bladder region in the CTAn package. The rate of
stone growth was tracked over a one month. At the end of the study, the linear mixed model with
random intercept was employed. Our data suggests that the rates of all three treatment groups
were similar and linear.

24

Table 4: Rate of Stone Growth per Treatment Group. N.S. – Not Significant
Treatment Group

Number of Mice

Vehicle Control
Sulforaphane
Methyl
Selenocysteine

6
5
6

Rate of Stone Growth
(mm3/day)
0.981
0.843
1.170
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p-value

N.S.
N.S.

Figure 7: Single Stone Tracker Contributes to Stone Accumulation. A single stone was tracked
weekly using the µCT scanner in a control Slc3a1-/- mouse. Linear regression revealed that the
rate of stone growth increased linearly with total stone volume. The correlation coefficient (R2)
was 0.96.
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II.

Effect of the Pharmacological Treatments in Reducing the Rate of
Cystine Stone Growth
To understand the effects of the interventions further, Slc3a1-/- mice without stones were

studied. In this study, the mice were treated intraperitoneally with vehicle control (n=6),
sulforaphane (n=6) and methyl selenocysteine(n=6) four weeks after birth. The doses were based
on previous studies. The dose of sulforaphane was based on a study conducted by Zheng et al.
(2011) that confirmed 12.5 mg/kg of the compound affects Nrf2 expression in the kidney. The
dose of methyl selenocysteine was based on a study conducted by Cao et al. (2014) that
confirmed the selective protective properties of Se- seleno methylcysteine against antitumor
activity and anticancer drugs.
The mice were treated three times a week and imaged weekly for four months using the
µCT scanner. Eventually, all the Slc3a1-/- mice formed stones. Body weights were recorded
weekly and remained consistent between the treatment groups (Figure 8). To compare the rates
of stone growth between the treatment groups, linear mixed model with random intercept was
employed and a linear correlation was found, indicating that the stone volume increased at a
linear rate (Figure 9). There was a statistical difference between the vehicle control and
sulforaphane groups (chisq=28.62, df=1, p<0.001) (Figure 10) and between sulforaphane and
methyl selenocysteine group (chisq-20.42, df=1, p<0.001). However, the difference between the
vehicle control and methyl selenocysteine group (chisq=2.74, df=1, p=0.098) was not
statistically significant. Overall, the slopes between the treatment groups were significantly
different (chisq=34.48, df=2, p<0.001) and sulforaphane showed a 15% reduction in the rate of
stone growth.
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This study was repeated using 20 Slc3a1-/- mice – 10 in vehicle control and 10 in a
sulforaphane treated group – for the duration of five months. Sulforaphane exhibited a similar
reduction of 18% in the rate of stone growth when compared to the vehicle control (chisq=4,
df=1, p=0.046) (Figure ___), further confirming sulforaphane as a potential pharmacological
intervention for cystinurics.
In order to understand the probability of having another stone event after a given time
point, a Kaplan-Meier survival plot was constructed. There were no significant differences across
the treatment groups (chisq=4.4, df=2. p=0.109) (Figure 12), indicating these interventions do
not possess preventative properties in cystine stone growth. Interestingly, by selecting for each
individual stone as a ROI in the CTAn package, individual stone volumes and the numbers of
stones in each size group were obtained and plotted in Figure 13. Stone size was then separated
into six size fractions (<1, 1-5, 5-10, 10-15, 15-20, 20-25, >25 mm3). Our data suggests that
sulforaphane produces medium sized stones.
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Figure 8: Body Weights per Treatment Group. Body weights were tracked weekly. There is no
significant difference between the body weights for the three treatment groups, indicating that
the treatment had no effect on body weight.
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Figure 9: The Rate of Stone Growth for the Treatment Groups. Each line represents an individual
Slc3a1-/- mouse in its respective treatment group. The thick solid lines are the estimated
trajectories for the rate of stone growth. Statistical differences were noted between the vehicle
control and sulforaphane groups and between the sulforaphane and methyl selenocysteine
groups. However, no significant difference was found between the methyl selenocysteine and
vehicle control groups.
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Figure 10: Sulforaphane Reduced the Rate of Stone Growth by 15%. Vehicle control and methyl
selenocysteine did not significantly reduce the rate of stone growth. However, sulforaphane
showed a 15% reduction in the rate of stone growth. *** Significantly different from the vehicle
control and methyl selenocysteiene treatment groups (p<0.001).
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Figure 11: Sulforaphane Displayed a Similar Reduction Pattern in the Rate of Stone Growth. The
study was repeated with vehicle control and sulforaphane treated groups. Statistical differences
were found between the vehicle control and sulforaphane. *** Significantly different from the
vehicle control group (p<0.001).
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Figure 12: Proposed Interventions Do Not Show Preventative Properties. Kaplan Meier plot was
used to determine the probability of having a stone event after a given period of time.
Differences between the treatment groups were not found, indicating that these interventions do
not possess preventative measures in reducing the rate of cystine stone growth.
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Figure 13: Sulforaphane Produces More Medium Sized Stones. Size distribution for each
individual mouse in all three treatments was performed by selecting for the region of interests
(ROIs) and using the CTAn package to obtain the volumetric measurements. Our results suggest
that sulforaphane has a preference for medium sized stones.
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Discussion and Conclusions
Cystinuria has been researched and redefined over the years. Medical management
currently consists of dietary modifications and urinary alkalization. Cystinurics are now
frequently given cystine-binding thiol drugs (CBTD) to reduce cystine accumulation and/or
increase cystine solubility in the urine. With the creation of the Slc3a1-/- mouse model for
cystinuria, questions regarding treatment options - what pharmacological interventions should be
investigated and what treatments should be given to reduce the rate of cystine growth - can be
better answered. In this study, we determined a) the feasibility of using the µCT scanner in
measuring 3D volumetric growth of the cystine stones and b) the efficacy of two
pharmacological interventions on the Slc3a1-/- mouse model in reducing the rate of cystine stone
growth.

I.

Micro-Computed Tomography (µCT) Scanning as a Novel Approach to
Tracking Stone Growth
The µCT scanner has become a popular model for mapping the internal structures and
surfaces in smaller organisms (Cavanaugh, 2004). The scanner has also been used in many
longitudinal studies requiring quantitative information of 3D volumetric measurement changes
during the lifespan of a small animal. While previous studies have employed the scanner to
measure trabecular and cortical bone volume and morphology in small animals at high resolution
(Yamashita, 2000; Bouxsein, 2010), measuring volumetric changes in stone volume at low
resolution in live animals has not been attempted. However, a study conducted by Ercolani et al.
(2010) revealed that the µCT scanner can be employed to visualize bladder stones in the Slc3a1-/mouse model. Based on this, we developed a protocol using the CTAn package to measure 3D
cystine stone volume over time and to also accurately measure the rate of cystine stone growth.
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From the developed protocol, three treatment groups – vehicle control, sulforaphane and methyl
selenocysteine – that had stones present in the bladder region were evaluated for at least a month.
Comparison of stone growth rate was evaluated using linear mixed model with random intercept.
Stone growth modeled by this system was shown to proceed linearly in all the treatment
groups (Figure 6 and Figure 9). To further confirm the volumetric advances in stone volume, the
size of a single stone was used as a marker for stone growth in the bladder. The single stone also
displayed linear growth with increases in total observed stone volume, indicating that this growth
contributes to the existing supersaturated solution in the bladder (Figure 7). This suggests that a
supersaturated environment may rise as a contributor to increased stone volume over time. A
previous study conducted by Ercolani et al. (2010) indicated that the environment provided by
the bladder may yield to crystal precipitation and eventually, intensify stone formation. With the
µCT scanner and the analysis packages, the scanner has provided valuable insight by delivering
accurate measurements of stone volume over a period of time in live small animals. Our results
support that the µCT scanner is a feasible instrument in determining the rate of stone growth
longitudinally.

II.

Sulforaphane as a Potential Therapeutic in Reducing the Rate of
Cystine Stone Growth
With the use of this novel approach, the comparison of the rate of stone growth were

calculated and evaluated using the linear mixed model with random intercept model. Our results
suggest that sulforaphane was shown to reduce the rate of stone growth by 15% when compared
to the vehicle control and methyl selenocysteine groups (Figure 10). This suggests that
sulforaphane is deliverable to the kidneys (Zheng, 2011) and may upregulate SLC7A11
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expression in the xc- system. A previous study reported that the Nrf2 had shown significant
upregulation in SLC7A11 expression in the human bladder cancer cell line, T24 (Ye, 2014).
Further studies investigating the link between Nrf2 and SLC7A11 may provide insights to the
mechanism through which this intervention functions. Also, understanding the mechanism of
action and the role of other Nrf2 activators in this mechanism are of interest.
An interesting observation from the study revealed that sulforaphane is associated with
medium sized stones when compared to the vehicle control and methyl selenocysteine groups
(Figure 12). This suggests that sulforaphane may be acting to promote medium size stone
formation and prevent the growth of large stones. This was seen in parallel with a study
conducted by Rimer et al. (2010) that showed CDME (l-cystine dimethylester) to promote small
stone formation in vitro. Because sulforaphane showed a reduced effect on the rate of stone
growth and the growth of medium sized stones, we conclude that sulforaphane may be a
potential therapeutic for cystinurics.

III.

Methyl Selenocysteine Did Not Show Any Effect in Reducing Cystine
Stone Growth

Methyl selenocysteine did not show a significant reduction in the rate of stone formation.
This suggests that methyl selenocysteine may not be delivered to the kidneys and may not have
converted to selenocysteine to dimerize with cysteine. Studies have suggested that synthesis of
selenocysteine is analogous that of cysteine; however, there is no evidence to support this claim
(Esaki 1981). Selenocysteine and cysteine also have been shown to affect glutathione activity in
mice and rats; however, no evidence was found indicating a conversion of selenocysteine to

37

cysteine (Watts, 2014). Further understanding is needed in determining the conversion of methyl
selenocysteine to cysteine in mammalian and mice tissue.
In order to obtain a chemical structure of the packing in cystine-based stones,
understanding the arrangement of atoms in cystine stones and its chemical composition is of
utmost importance. We hypothesized that selenocysteine would dimerize with cysteine and that
the packing of the cystine stones was thought to be disrupted. However, our results suggest that
selenocysteine may not have affected the packing of heterogeneous cystine stones and therefore,
may not have displayed a significant change to the overall structure of the stones. When the
crystals are packed closely together, the atomic radii may have assumed a larger distance
between the molecules, giving rise to non affected cystine stones. Therefore, no significant
changes were recorded in the Slc3a1-/-mouse model. Further studies will need to be done to
confirm this possibility. Finally, a Kaplan-Meier plot was constructed to determine the
probability of having another stone event (Figure 11). No significant differences were found
between the treatment groups, indicating that these interventions do not possess preventative
measures. Further analysis is still needed in understanding the preventative properties of
cystinuria.

IV.

Future Directions

While the pathophysiology of the cystine transport systems are widely known, studies
can be conducted in evaluating deficiencies in the rBAT-b0,+ AT transporter and the xc- system.
In addition, understanding how these interventions affect the cystine transporters is also of
interest. The interventions used in this study were chosen based on previous studies.
Understanding the mechanism of how the interventions are received and processed in the kidney
might provide insight in determining and evaluating newer interventions, such as other Nrf2
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activators. Further studies should also evaluate the Nrf2 properties should be determined in
whether Nrf2 can increase the expression of the xc-transporter and cystine. A combination of
these therapies may also yield to progression in understanding treatment options for cystinurics.
With the developed protocol, this study was able to use the in vivo µCT scanner in
confirming the feasibility of tracking stone growth longitudinally. By using the analysis
packages, the study was also able to evaluate the efficacy of the interventions in reducing the rate
of cystine stone growth in the Slc3a1-/- mice model. These approaches displayed a linear growth
in total stone volume that can be visualized through 3D models and quantified through the CTAn
package. Changes in stone size distribution provided insight into the phenotypic effects of the
interventions used. The intervention, sulforaphane, showed promise as a preventative therapeutic
for cystinurics by displaying a reduction in the rate of stone growth. With this approach,
evaluating potential therapeutics in the Slc3a1-/-cystinuric mouse model will further our
understanding and will provide newer interventions for cystinurics.
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Addendum
Introduction
By using the established protocol, three additional interventions – homocysteine,
tiopronin and TPEN – and a zinc-supplemented diet were evaluated for their ability to prevent
cystine stone formation and/or reduce the rate of cystine stone growth.

Effect of Homocysteine and Tiopronin in Reducing the Rate of Cystine Stone
Growth
Homocysteine is a homologue of the amino acid, cysteine. It is formed from methionine
and is an intermediate in the methionine pathway. Homocysteine can be removed through the
remethylation or trans-sulfuration pathway (Wu, 2012). The trans-sulfuration pathway is most
related to cystinuria, in which homocysteine is readily converted to cystathionine and
subsequently to cysteine, a process that mainly takes place in the kidneys. Based on the Rimer et
al. (2010) study and the proposal for methyl selenocysteine, homocysteine is hypothesized to
generate an asymmetric cysteine-homocysteine dimer. The packing of the stones will be
disrupted, yielding to a reduced rate of cystine stones.
Tiopronin is an amino thiol, antioxidant compound that is currently administered to
cystinuric patients (Barbey, 2000; Chow, 1966). Tiopronin functions in many capacities
including acting as a chelating agent, and has cardio- and radio-protecting properties
(Penugonda, 2004). Due to the free sulfhydryl group, it is highly sensitive to oxidation and can
readily form disulfide dimmers with other sulfhydryls (Leroy, 1991). This suggests that
administering tiopronin can break the disulfide bond in cystine and form a bond with cysteine
(Barbey, 2000). For the basis of our study, tiopronin is thought to also form asymmetric cysteine
–tiopronin dimer, leading to a reduction in the rate of stone growth.
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Homocysteine and Tiopronin were freshly prepared daily prior to administering. Each
cohort received the respective dose, administered three times per week through intraperitoneal
(IP) injections for the duration of the study. Homocysteine and tiopronin were dissolved in PBS.
Control mice for the homocysteine and tiopronin groups received PBS only. Mice were
randomized to avoid bias before being placed in the treatment groups. Preparation and dosage
are summarized in Table 5.
.
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Table 5: Preparation and Doses for Homocysteine and Tiopronin.
Treatment

Preparation

Dosage

Homocysteine

Dissolved in PBS

8.11mg/kg

Tiopronin

Dissolved in PBS

18.4mg/kg
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A total of 11 male cystinuric mice were observed under the µCT scanner to ensure that
the Slc3a1-/- mice had not formed cystine stones prior to the initiation of the study. At two
months of age, the Slc3a1-/- mice were randomly placed in three cohorts – vehicle control (n=5),
Homocysteine (n=2) and Tiopronin (n=4). The doses were chosen based on previous studies. The
dose of homocysteine was based on dosage administered to humans and adjusted for mice. The
dose of Tiopronin was based on the calculation used to determine L-CDME administration in the
Rimer et al. (2010) study. The mice were imaged weekly for three months using the µCT
scanner. Eventually, all the Slc3a1-/-mice formed stones. To compare the rates of stone growth
between the treatment groups, linear mixed model with random intercept was employed.
Linear mixed model with random intercept was used to compare the rate of stone growth
between the treatment groups. Stone growth for the treatment groups proceeded at a linear rate.
Both homocysteine (chisq=28.05, df=1, p<0.001) (Figure 14) and Tiopronin (chisq=2.81, df=1,
p=0.094) (Figure 15) were statistically different from the vehicle control. However, both
compounds increased the rate of stone growth as opposed to reducing the rate.
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Figure 14: Homocysteine Worsens Cystine Stone Growth. Statistical differences were found
when the homocysteine treatment group was compared to the vehicle control group. However,
the differences displayed an increased rate of stone growth as opposed to a reduction.
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Figure 15: Tiopronin Worsens Cystine Stone Growth Rate. Statistical differences were found
between the Tiopronin treatment groups and the vehicle control group. However, the differences
displayed an increased rate of stone growth as opposed to a reduction.
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Effect of TPEN and Zinc-Supplemented Diet in Reducing the Rate of Cystine
Stone Growth
N, N, N′, N′-tetrakis (2-pyridylmethyl)-ethyenediamine (TPEN) is a Zn2+/ Fe2+chelator
(Shumaker, 1998). Studies have shown that the administration of TPEN decreases zinc levels in
the kidney (Li, 2013; Li, 2014; Hamon, 2014). Zinc is an essential trace element that has
antioxidant properties and is associated with diabetes. In the Kapahi lab (Chi, unpublished data),
zinc was found to promote urinary concretions in a Drosophila Melanogaster (fruit fly) model of
chronic stone disease. In addition, and zinc was detected in the center of the stones (Figure 16).
TPEN and a zinc-supplemented diet were hypothesized to affect the bioavailability of zinc in the
Slc3a1-/- mice, thereby reducing the rate of stone growth.
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Figure 16: Zinc Detection in Cystine Stones. Zinc was shown to be present at the center of in a
cystine stone.
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TPEN was freshly prepared daily prior to administering. The TPEN and vehicle control
cohorts received the respective dose, administered four to five times per week through
intraperitoneal (IP) injections for the duration of the study. TPEN was kept in stock solution of
100% EtOH and diluted to 5% with the addition of PBS. Control mice in this group received 5%
EtOH in PBS only. The zinc-supplemented diet was prepared by Harlan Laboratories (Haslett,
Ml). Control mice for this diet received Harlan Irradiated Pellet Rodent Diet (chow diet). All
animals from zinc-supplemented cohort were fed weekly. Animals were randomized to avoid
bias before being placed in the treatment groups. Preparation and dosage are summarized in
Table 6.

48

Table 6: Preparation and Doses for TPEN and Zinc-Supplemented Diet.
Treatment

Preparation

Dosage

TPEN

Stock Solution in 100% EtOH. 25mg/kg
Administered in 5%EtOH in
PBS

Zinc-Supplemented Diet

Prepared by Harlan
Laboratories
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250 ppm

A total of 33 male SLC3a1-/- mice were observed under the µCT scanner to ensure that
cystine stones had not formed prior to the initiation of the study. At the age of two months, the
Slc3a1-/- mice were placed in two cohorts – vehicle control (n=8) and TPEN (n=7). At one month
of age, another cohort of Slc3a1-/-mice were placed in two groups – vehicle control (n=8) and
zinc-supplemented diet (n=10). The mice were imaged weekly for three months using the µCT
scanner. Eventually, all of the Slc3a1-/-mice formed stones.
Linear mixed model with random intercept was employed, yielding the rate of growth.
Stone growth for both treatments proceeded at a linear rate. There was a statistical difference
between the vehicle control and TPEN group (chisq=10.71, df=1, p=0.001), indicating that
TPEN may be an effective treatment for cystinurics. TPEN was shown to reduce the rate of
cystine stone growth by 18% (Figure 17). However, no statistical difference was found in the
zinc-supplemented diet (chisq=0.005, p=0.943) (Figure 18).

50

Figure 17: TPEN Reduced the Rate of Cystine Stone Growth by 18%. Statistical differences
were found between the TPEN and vehicle control treatment groups.
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Figure 18: Zinc-Supplemented Diet Did Not Display Any Effect on Cystine Stone Growth Rate.
There were no statistical differences between the zinc-supplemented diet group and the vehicle
control group.
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Discussion and Conclusions
I.

Homocysteine Worsened Cystine Stone Growth
In this study, we were able to evaluate three additional interventions– homocysteine,

tiopronin and TPEN - and a zinc-supplemented diet – in reducing the rate of cystine stone
growth. All interventions and the supplemented diet displayed a linear growth pattern. However,
homocysteine and tiopronin were shown to increase the rate of stone formation in our Slc3a1-/cystinuric model. This suggests that homocysteine may not have converted to cysteine to form a
dimer or may have prompted the formation of cystine. Homocysteine has also been shown to
bind to proteins, allowing its exportation out of the cell (Svardal, 1986). This suggests that
protein-protein interactions may have taken place within the cell. Further understanding is
needed in the proteins interactions within and between cystine, cysteine and homocysteine in the
urine.

II.

Currently Prescribed, Tiopronin, Did Not Reduce the Rate of
Cystine Stone Growth
In addition to homocysteine, tiopronin, a prescribed medication for cystinuric patients,

also displayed an increased rate of stone growth. This is contradicted by multiple studies that
have shown that tiopronin treatment is critical to treatment of cystinuria. These studies have
shown that with tiopronin treatment, cystine excretion was remarkedly higher in cystinuric
patients (Joly, 1999). However, its effectiveness is debated. Toxicity was a possibility; however
a study conducted by Zhang et al. (1999) revealed that with tiopronin treatment, nephrotoxic
effects in in vivo rat kidneys were protected. This indicates that tiopronin may have acted to
protect kidney function as opposed to forming cysteine dimmers.
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III.

Zinc Bioavailability May Affect Cystine Stone Growth

Our results confirmed the efficacy of TPEN in reducing the rate of stone growth and that
zinc-supplemented displayed no effect. This suggests that TPEN is deliverable to the kidneys
(Tainer, 1982) and the chelating properties of zinc may have affected zinc bioavailability in the
cystine stones. Interestingly, a study conducted by Ho et al. (2003) revealed that p53 expression,
a tumor suppressor, is increased by zinc depletion. Another study conducted by Jiang et al.
(2015) revealed that p53 plays a role in inhibiting cystine uptake through the reduced of
SLC7A11. In addition, zinc homeostasis is heavily regulated, indicating that zinc may have not
been absorbed and therefore, may have been excreted; however, further studies will need to be
conducted to confirm the possibility.

IV.

Future Directions

Future studies in understanding the roles of homocysteine, TPEN and zinc bioavailability
may provide further knowledge in the role of zinc and p53 in cystinuria as well as the
mechanistic action that is taking place. Finally, evaluating early stones and late stones may
provide new knowledge in the how the treatments are configured in the mouse cystinuric model.
With the evaluation of the presented and future therapeutics, the incident of stone formation will
decrease for cystinurics and will be a presentable treatment option.
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